Exponent (EXPO) Lifted Guidance, Is The Stock Still A Bargain?
Exponent (EXPO) drew investor attention after raising its full year and third quarter 2026 revenue growth guidance, while also reporting higher second quarter sales, revenue and net income, and confirming both its dividend and expanded share repurchase program.
See our latest analysis for Exponent.
The recent guidance upgrade and confirmed capital return plans appear to have improved sentiment around Exponent, with a 30-day share price return of 10.06% and a 90-day share price return of 25.32%. However, the 1-year total shareholder return is still down 1.93% and the 5-year total shareholder return is down 35.89%.
If this kind of renewed interest has you looking beyond a single stock, it can be a good time to scan the market for other companies showing solid execution and momentum using the 19 top founder-led companies
Bulls point to Exponent’s higher revenue guidance, strong recent quarter and larger buyback, while bears focus on multi-year underperformance. Which side does the current valuation evidence appear to support?
Most Popular Narrative: 16.3% Undervalued
The most followed narrative sees Exponent trading below its estimated fair value of $81.67 compared with the last close of $68.35, and ties that gap to a detailed view of future earnings power and capital returns.
Ongoing expansion into high-growth, innovation-driven domains, including artificial intelligence safety, distributed energy systems, and advanced medical technologies, broadens Exponent's addressable market and client base. This is described as setting up an accelerating revenue trajectory as these industries scale. Strengthening headcount growth, propelled by effective recruiting and a development-focused culture, is seen as enabling Exponent to capture more project volume and maintain its reputation-driven pricing power, with positive implications stated for both top-line growth and sustained high net margins.
Want to see what sits underneath that fair value for Exponent? The narrative leans on steady revenue growth, resilient margins and a richer earnings multiple. Curious which assumptions really move the dial on that $81.67 figure?
Result: Fair Value of $81.67 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear watchpoints for Exponent, including softer utilization and flat net revenues. These factors could pressure margins and challenge the premium P/E narrative.
Find out about the key risks to this Exponent narrative.
Another View on Exponent’s Valuation
The first narrative frames Exponent as 16.3% undervalued based on a fair value of $81.67. A different lens uses its P/E of 29.1x versus a peer average of 20.3x and a fair ratio of 17.4x. This perspective points to a richer price tag and a higher risk of multiple compression. Which story do you think fits best?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment split between Exponent’s recent momentum and its multi year share price pressure, it makes sense to look at the numbers yourself and move quickly to shape your own view using the 5 key rewards and 1 important warning sign.
Looking For More Investment Ideas Beyond Exponent?
If you are weighing Exponent but still want broader opportunities, now is a good time to widen your search and compare different types of stocks side by side.
Use the Simply Wall Street Screener to quickly surface focused ideas before the market moves without you.
- Spot potential income anchors for your portfolio by reviewing companies in the 9 dividend fortresses.
- Hunt for quality at a reasonable price by scanning the 51 high quality undervalued stocks.
- Prioritise resilience and capital preservation by checking out the 83 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com